BRAF and Hypertension: The decision to start with drug targeting METex14 skipping was made based on the patient’s preference and medical history of cerebral aneurysm and the corresponding higher requirements for drug safety, as nervous system adverse reactions, such as dizziness and headache, and vascular adverse reactions, such as hypertension and subarachnoid hemorrhage, have been reported in patients treated with BRAF inhibitors (15).